IntegraGen SA (EPA:ALINT)

Market Cap	1.26M -63.3%
Revenue (ttm)	5.02M -42.3%
Net Income	-2.66M
EPS	-0.40
Shares Out	6.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Open	0.1915
Previous Close	0.1915
Day's Range	0.1915 - 0.1915
52-Week Range	0.1150 - 0.5500
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2026

About IntegraGen

IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company’s genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; Ga...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 37
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALINT

Financial Performance

In 2025, IntegraGen's revenue was 5.02 million, a decrease of -42.27% compared to the previous year's 8.70 million. Losses were -2.66 million, 940.6% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 24, 2026

Data Sources Report a data error